Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT ...

Gain Therapeutics announces positive Phase 1 results for GT-02287, showing safety, tolerability, and target engagement, on track for Phase 1b trial in Q4 2024.